|
|
|
Pulmonary hypertension: a neglected risk condition in renal patients? |
Davide Bolignano1, *( ), Anna Pisano1, Graziella D’Arrigo1 |
1 CNR-Institute of Clinical Physiology, 89124 Reggio Calabria, Italy |
|
|
Abstract: Pulmonary hypertension (PH), an acknowledged risk condition at the community level and in patients with heart or lung diseases, is now getting growing attention as a new, potentially modifiable cardiovascular (CV) risk factor also in individuals affected by kidney diseases. PH is highly prevalent in this setting, being about 3 to 6 times more frequent that in the general population and portends a risk excess for mortality, adverse CV outcomes and also worsen graft function in kidney transplant recipients. Several factors might be involved to explain PH in renal patients, including but not limited to volume overload, breath disorders, left heart dysfunction and the presence of highflow artero-venous fistulas. Targeting PH might lead to improved outcomes in renal patients but the lack of specific interventional studies and the need for more accurate evidence adopting standardized ways to assess PH leave the issue open for future research.
|
Published: 30 December 2018
|
*Corresponding Author(s):
Davide Bolignano, E-mail: davide.bolignano@gmail.com
|
[1] Abassi z, Nakhoul f, Khankin e, et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens. 2006;15:353-360. [2] Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant. 2012;27: 3908-3914. [3] Arrigoni FI, Vallance P, Haworth SG. et al. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation. 2003;107:1195-1201. [4] Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55-S66. [5] BarcelóA, de la Pe?a M, AYLLON O, et al. Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration. 2009;77:85-90. [6] Bolignano D, Lennartz S, Leonardis D, et al. High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2-4 chronic kidney disease. Kidney Int. 2015;88:130-136. [7] Bolignano D, Pisano A, Coppolino G, et al. Pulmonary Hypertension Predicts Adverse Outcomes in Renal Patients: A Systematic Review and Meta-Analysis. Ther Apher Dial. 2018 Nov 22. [8] Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013;61:612-622. [9] Buemi M, Senatore M, Gallo GC, et al. Pulmonary hypertension and erythropoietin. Kidney Blood Press Res. 2007;30:248-252. [10] Eggers PW. Has the incidence of end-stage renal disease in the USA and other countries stabilized? Curr Opin Nephrol Hypertens. 2011;20:241-245. [11] Fabbian F, Cantelli S, Molino C, et al. Pulmonary hypertension in dialysis patients: a cross-sectional italian study. Int J Nephrol. 2010;30 . [12] Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263. [13] George MG, Schieb LJ, Ayala C, et al. Pulmonary hypertension surveillance: United States, 2001 to 2010. Chest. 2014;146:476-495. [14] Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest. 1998;114:208S-212S. [15] Havlucu Y, Kursat S, Ekmekci C, et al. Pulmonary hypertension in patients with chronic renal failure. Respiration. 2007;74:503-510. [16] Honeycutt AA, Segel JE, Zhuo X, et al. Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013;24:1478-1483. [17] Hyduk A, Croft JB, Ayala C, et al. Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveill Summ. 2005;54:1-28. [18] Issa N, Krowka MJ, Griffin MD, et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation. 2008;86:1384-1388. [19] Kiykim AA, Horoz M, Ozcan T, et al. Pulmonary hypertension in hemodialysis patients without arteriovenous fistula: the effect of dialyzer composition. Ren Fail. 2010;32:1148-1152. [20] Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146-1150. [21] Lam CS, Borlaug BA, Kane GC, et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119:2663-2670. [22] Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12:143-155. [23] Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant. 2005;20:1686-1692. [24] Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003;42:303-309. [25] Pabst S, Hammerstingl C, Hundt F, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One. 2012;7:1-7. [26] Ramasubbu K, Deswal A, Herdejurgen C, et al. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med. 2010;3:279-286. [27] Ryan JJ, Thenappan T, Luo N, et al. The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulm Circ. 2012;2:107-121. [28] Sakaguchi Y, Shoji T, Kawabata H, et al. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a crosssectional study. Clin J Am Soc Nephrol. 2011;6:995-1000. [29] Sasaki A, Doi S, Mizutani S, et al. Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1480-L1487. [30] Sica AL, Greenberg HE, Ruggiero DA. et al. Chronic-intermittent hypoxia: a model of sympathetic activation in the rat. Respir Physiol. 2000;121:173-184. [31] Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43-S54. [32] Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012;98:1805-1811. [33] Ward JP, Mcmurtry IF. Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr Opin Pharmacol. 2009;9:287-296. [34] Yigla M, Fruchter O, Aharonson D, et al. Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int. 2009;75:969-975. [35] Yigla M, Keidar Z, Safadi I, et al. Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values. Kidney Int. 2004;66:806-810. [36] Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003;123:1577-1582. [37] Zlotnick, DM, Axelrod DA, Chobanian MC, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant. 2010;25:3090-3096. [38] Zoccali C. The endothelium as a target in renal diseases. J Nephrol. 2007;20:S39-S44. [39] Zoccali C, Bode-boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-2117. |
No Suggested Reading articles found! |
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|